Literature DB >> 31287594

Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice.

E H Taudorf1,2, G B E Jemec1,2, R J Hay3, D M L Saunte1,2.   

Abstract

Cutaneous candidiasis is a common skin disease, and several treatments have been investigated within the last fifty years. Yet, systematic reviews are lacking, and evidence-based topical and systemic treatment strategies remain unclear. Thus, the aim of this review was to summarize efficacy and adverse effects of topical and oral therapies for cutaneous candidiasis in all age groups. Two individual researchers searched PubMed and EMBASE for 'cutaneous candidiasis' and 'cutaneous candidiasis treatment', 'intertrigo', 'diaper dermatitis' and 'cheilitis'. Searches were limited to 'English language', 'clinical trials' and 'human subjects', and prospective clinical trials published in abstracts or articles were included. In total, 149 studies were identified, of which 44 were eligible, comprising 41 studies of 19 topical therapies and four studies of three systemic therapies for cutaneous candidiasis. Topical therapies were investigated in infants, children, adolescents, adults and elderly, while studies of systemic therapies were limited to adolescents and adults. Clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated similar efficacy with complete cure rates of 73%-100%. Single-drug therapy was as effective as combinations of antifungal, antibacterial and topical corticosteroid. Four studies investigated systemic therapy, and oral fluconazole demonstrated similar efficacy to oral ketoconazole and topical clotrimazole. Limitations to this review were mainly that heterogeneity of studies hindered meta-analyses. In conclusions, clotrimazole, nystatin and miconazole were the most studied topical drugs and demonstrated equal good efficacy and mild adverse effects similar to combinations of antifungal, antibacterial and topical corticosteroids. Oral fluconazole was as effective as topical clotrimazole and is the only commercially available evidence-based option for systemic treatment of cutaneous candidiasis.
© 2019 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31287594     DOI: 10.1111/jdv.15782

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  5 in total

1.  Does the Freeze-Thaw Technique Affect the Properties of the Alginate/Chitosan Glutamate Gels with Posaconazole as a Model Antifungal Drug?

Authors:  Marta Szekalska; Katarzyna Sosnowska; Magdalena Wróblewska; Anna Basa; Katarzyna Winnicka
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

2.  Small, Cationic Antifungal Proteins from Filamentous Fungi Inhibit Candida albicans Growth in 3D Skin Infection Models.

Authors:  Jeanett Holzknecht; Sandrine Dubrac; Sarah Hedtrich; László Galgóczy; Florentine Marx
Journal:  Microbiol Spectr       Date:  2022-05-02

3.  [Management of cutaneous and systemic involvement by Candida auris].

Authors:  C Roig Martí; J J Jiménez Sierra; I Pérez Catalán; S Gomila Sard; A Cardenal Álvarez; M D Bellés Medall
Journal:  Rev Esp Quimioter       Date:  2021-11-30       Impact factor: 1.553

4.  Antifungal susceptibility pattern of Candida isolated from cutaneous candidiasis patients in eastern Guangdong region: A retrospective study of the past 10 years.

Authors:  Hazrat Bilal; Bing Hou; Muhammad Shafiq; Xinyu Chen; Muhammad Akbar Shahid; Yuebin Zeng
Journal:  Front Microbiol       Date:  2022-08-05       Impact factor: 6.064

5.  Overdiagnosis and overtreatment of nipple and breast candidiasis: A review of the relationship between diagnoses of mammary candidiasis and Candida albicans in breastfeeding women.

Authors:  Pamela Douglas
Journal:  Womens Health (Lond)       Date:  2021 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.